ERBA Mannheim’s CE Marked Covid-19 antibody ELISA kits allow qualitative and semi-quantitative detection of the IgG and IgM antibodies. Credit: National Institute of Allergy and Infectious Diseases, NIH.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

ERBA Mannheim is set to launch its CE Marked ErbaLisa Covid-19 antibody ELISA kits in response to the global Covid-19 pandemic.

The tests can be used manually or can be run on any open automated ELISA analyser such as the Erba Mannheim ELAN 30s.

In addition, the ready-to-use ELISA antibody kits allow the qualitative and semi-quantitative detection of the IgG and IgM antibodies to SARS-CoV-2 produced in the body in response to Covid-19.

IgM, which is produced first, can be detected during the early stage of the disease. IgG is produced later and is maintained for long-term immunity.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Erba Mannheim Immunoassay global product manager Petros Sarantos said: “Our IgM test could be used to identify people recently infected by the virus, including those who may not have displayed symptoms. The IgG test will provide an accurate measure of how many people have been infected and may have developed an immunity.

“Once identified, immune individuals could safely return to work and help relieve stressed healthcare systems or other frontline functions. Such people could also donate their blood to potentially save other patients with severe Covid-19.”

The ErbaLisa Covid-19 assays have been designed, developed at Calbiotech Erba Mannheim’s immunoassay centre of excellence in El Cajon, California, where they will also be manufactured.

Erba Mannheim managing director Nikhil Vazirani said: “We are very proud to be contributing towards the fight against Covid-19. Having a better understanding of the immunity of Covid-19 will help society move back towards normality.”

The company is currently seeking the US Food and Drug Administration’s (FDA) emergency use authorisation (EUA) for both assays.

The kits will be distributed through its global distribution network, including in the US.